through the
暂无分享,去创建一个
J. M. Fernández-Rodríguez | N. Lorenzo-Villalba | J. García-Klepzig | Á. González-Franco | J. Casas-Rojo | P. Díaz-Jimènez | J. Miramontes-González | L. Moreno-Gaviño | B. Sánchez-Sauce | F. J. Carrasco-Sánchez | R. Aparicio-Santos | J. Ternero-Vega | P. Llácer-Iborra | J. Barrado-Cuchillo | I. Vallejo-Maroto | P. Casado-Escribano | C. Conde-Guzmán | M. Ollero‐Baturone | M. Rubio-Rivas | D. Nieto‐Martín | F. J. Martín-Sánchez | M. Bernabeu‐Wittel | J. M. de-Miguel-Yanes | J. Díez-Manglano | L. Manzano-Espinosa | S. Gutiérrez-Rivero | C. Jimènez-Juan | R. Iguarán-Bermúdez | M. Villar-Martínez | M. Méndez-Bailón | M. Rincón-Gómez | L. Giménez-Miranda | C. Washburn | V. Gundareddy | F. Kisuule | S. Fernández | P. Pérez-Mateo | L. López-García | E. Calvo-Manuel | L. M. Beltrán-Romero | A. García-García | E. Andres | M. D. R. Gómez-Huelgas | J. García-de-Lucas | J. Ena | Carretero-Gómez | M. Bernabeu-Wittel
[1] B. Resnick,et al. Pain Management in the Post-acute and Long-Term Care Setting: A Clinical Practice Guideline (CPG) from the Society for Post-acute and Long-Term Care Medicine (AMDA). , 2021, Journal of the American Medical Directors Association.
[2] S. Arora,et al. Early and Significant Reduction in C-Reactive Protein Levels After Corticosteroid Therapy Is Associated With Reduced Mortality in Patients With COVID-19. , 2021, Journal of hospital medicine.
[3] C. Campochiaro,et al. The clinical phenotype of Systemic Sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. , 2021, Rheumatology.
[4] E. Howell,et al. Caring for Patients at a COVID-19 Field Hospital. , 2021, Journal of hospital medicine.
[5] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.
[6] D. Schoenfeld,et al. Safety Assessment of a Noninvasive Respiratory Protocol for Adults with COVID-19. , 2020, Journal of hospital medicine.
[7] A. McWilliams,et al. Insights From Rapid Deployment of a “Virtual Hospital” as Standard Care During the COVID-19 Pandemic , 2020, Annals of Internal Medicine.
[8] G. Filippatos,et al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes , 2020, Circulation.
[9] M. Méndez-Bailon,et al. Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized With COVID-19 in Spain , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.
[10] G. Filippatos,et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.
[11] O. Wazni,et al. Clinical Characteristics and Outcomes of Non-ICU Hospitalization for COVID-19 in a Nonepicenter, Centrally Monitored Healthcare System. , 2020, Journal of hospital medicine.
[12] Leora I. Horwitz,et al. Trends in COVID-19 Risk-Adjusted Mortality Rates. , 2020, Journal of hospital medicine.
[13] L. Jacobs,et al. Physician Workforce Response to the COVID-19 Pandemic at an Academic Medical Center , 2020, Disaster medicine and public health preparedness.
[14] Richard S. Henry,et al. Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study , 2020, Journal of Psychosomatic Research.
[15] B. Thombs,et al. Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma Patient-centred Intervention Network (SPIN) Cohort Study , 2020, BMJ Open.
[16] L. Czirják,et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database , 2020, Annals of the Rheumatic Diseases.
[17] J. McMurray,et al. Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.
[18] C. Cannon,et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.
[19] M. Sim,et al. Occupational silica exposure in an Australian systemic sclerosis cohort. , 2020, Rheumatology.
[20] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure , 2020, New England Journal of Medicine.
[21] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[22] D. Furst,et al. Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials. , 2020, Clinical and experimental rheumatology.
[23] N. Ortego-Centeno,et al. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). , 2020, Rheumatology.
[24] M. Bernabeu-Wittel,et al. Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks , 2020, Archives of Gerontology and Geriatrics.
[25] Corey Scurlock,et al. Rapid Implementation and Adaptation of a Telehospitalist Service to Coordinate and Optimize Care for COVID-19 Patients. , 2020, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[26] S. Agarwal,et al. Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. , 2020, Journal of hospital medicine.
[27] M. Bernabeu-Wittel,et al. Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.
[28] J. Ramos-Rincón,et al. Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry , 2020, Revista Clínica Española (English Edition).
[29] A. Keniston,et al. Harnessing the Power of Hospitalists in Operational Disaster Planning: COVID-19 , 2020, Journal of General Internal Medicine.
[30] J. M. Fernández-Rodríguez,et al. Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. , 2020, Revista clinica espanola.
[31] M. Inzitari,et al. Nursing Homes and Long Term Care After COVID-19: A New ERA? , 2020, The journal of nutrition, health & aging.
[32] T. Brooks,et al. Pooled Testing for SARS-CoV-2 in Hospitalized Patients. , 2020, Journal of hospital medicine.
[33] S. Jimenez,et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. , 2020, Rheumatology.
[34] A. Evans,et al. Inpatient Management of COVID-19 Pneumonia: a Practical Approach from the Hospitalist Perspective , 2020, Journal of General Internal Medicine.
[35] Benji K. Mathews,et al. Clinical Progress Note: Point-of-Care Ultrasound Applications in COVID-19. , 2020, Journal of hospital medicine.
[36] W. McDonald,et al. Altered Mental Status as a Novel Initial Clinical Presentation for COVID-19 Infection in the Elderly , 2020, The American Journal of Geriatric Psychiatry.
[37] L. Tan,et al. COVID-19 outbreak in nursing homes in Singapore , 2020, Journal of Microbiology, Immunology and Infection.
[38] J. Karlawish,et al. Ethics of reallocating ventilators in the covid-19 pandemic , 2020, BMJ.
[39] David J. Warne,et al. Hindsight is 2020 vision: a characterisation of the global response to the COVID-19 pandemic , 2020, BMC Public Health.
[40] Denise D. Quigley,et al. COVID‐19 Preparedness in Nursing Homes in the Midst of the Pandemic , 2020, Journal of the American Geriatrics Society.
[41] T. Mehmood,et al. Inpatient Care of Patients with COVID-19: A Guide for Hospitalists , 2020, The American Journal of Medicine.
[42] M. Worm,et al. Older age onset of systemic sclerosis – accelerated disease progression in all disease subsets , 2020, Rheumatology.
[43] P. Kaboli,et al. Perceived Need and Potential Applications of a Telehospitalist Service in Rural Areas. , 2020, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[44] R. Harwood,et al. Atypical presentation of COVID-19 in a frail older person , 2020, Age and ageing.
[45] D. O’Neill,et al. COVID-19 in Nursing Homes , 2020, QJM : monthly journal of the Association of Physicians.
[46] A. G. Rada,et al. Covid-19: the precarious position of Spain’s nursing homes , 2020, BMJ.
[47] J. Kirkpatrick,et al. ASE Statement on Point-of-Care Ultrasound during the 2019 Novel Coronavirus Pandemic , 2020, Journal of the American Society of Echocardiography.
[48] L. Magnani,et al. Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum. , 2020, Clinical and experimental rheumatology.
[49] P. Davidson,et al. Nursing homes and COVID‐19: We can and should do better , 2020, Journal of clinical nursing.
[50] P. Kaboli,et al. Using Telehealth as a Tool for Rural Hospitals in the COVID‐19 Pandemic Response , 2020, The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association.
[51] C. Mannelli. Whose life to save? Scarce resources allocation in the COVID-19 outbreak , 2020, Journal of Medical Ethics.
[52] Daniel E Trucil. American Geriatrics Society Policy Brief: COVID‐19 and Nursing Homes , 2020, Journal of the American Geriatrics Society.
[53] Aditi Balakrishna,et al. Calculated decisions: COVID-19 calculators during extreme resource-limited situations. , 2020, Emergency medicine practice.
[54] C. Tai,et al. The Impact of the COVID-19 Pandemic on Disabled and Hospice Home Care Patients , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.
[55] WHO must prioritise the needs of older people in its response to the covid-19 pandemic , 2020, BMJ.
[56] G. Dumyati,et al. Unprecedented Solutions for Extraordinary Times: Helping Long-Term Care Settings Deal with the COVID-19 Pandemic , 2020, Infection Control & Hospital Epidemiology.
[57] T. Rea,et al. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington , 2020, The New England journal of medicine.
[58] Lisa Rosenbaum,et al. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. , 2020, The New England journal of medicine.
[59] N. Ortego-Centeno,et al. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation. , 2020, Autoimmunity reviews.
[60] Giacomo Grasselli,et al. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. , 2020, JAMA.
[61] M. Hudson,et al. An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. , 2020, Seminars in arthritis and rheumatism.
[62] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[63] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[64] R. Gomis,et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study , 2020, Scientific Reports.
[65] M. Matucci-Cerinic,et al. Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. , 2020, Seminars in arthritis and rheumatism.
[66] N. Ortego-Centeno,et al. Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement. , 2020, Clinical and experimental rheumatology.
[67] Introduction: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.
[68] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.
[69] D. Mikhailidis,et al. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box! , 2019, Metabolism: clinical and experimental.
[70] G. Hindricks,et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.
[71] A. Levin,et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. , 2019, The lancet. Diabetes & endocrinology.
[72] Ami A. Shah,et al. Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry , 2019, Clinical Rheumatology.
[73] B. Zinman,et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial. , 2019, Age and ageing.
[74] B. Thombs,et al. Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study , 2019, BMJ Open.
[75] J. McMurray,et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.
[76] B. Zinman,et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. , 2019, JAMA.
[77] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[78] J. Lovshin,et al. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials. , 2019, Canadian journal of diabetes.
[79] F. Spertini,et al. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis , 2019, Arthritis & rheumatology.
[80] M. Hudson,et al. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. , 2019, Rheumatology.
[81] R. Sauter,et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis , 2019, Annals of the rheumatic diseases.
[82] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[83] R. Gómez-Huelgas,et al. Analysis of hospitalizations by cardiovascular disease in the population with diabetes in Spain , 2019, Revista Clínica Española (English Edition).
[84] M. Hudson,et al. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis , 2019, Annals of the rheumatic diseases.
[85] C. Denton,et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort , 2019, Annals of the rheumatic diseases.
[86] Deepak L. Bhatt,et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.
[87] D. Khanna,et al. Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features , 2019, RMD Open.
[88] N. Ortego-Centeno,et al. Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis–associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study , 2019, The Journal of Rheumatology.
[89] Leslie E. Mueller,et al. The SHIELD Orange County Project -Multi Drug-Resistant Organism (MDRO) Prevalence in 21 Nursing Homes and Long Term Acute Care Facilities in Southern California. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] U. Müller-Ladner,et al. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey , 2019, Arthritis Research & Therapy.
[91] Charles M. LoPresti,et al. Point-of-Care Ultrasound for Hospitalists: A Position Statement of the Society of Hospital Medicine. , 2019, Journal of hospital medicine.
[92] Marc P. Bonaca,et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.
[93] M. Raji,et al. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus , 2019, Therapeutic advances in chronic disease.
[94] N. Ortego-Centeno,et al. Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry , 2018, Clinical Rheumatology.
[95] M. Hudson,et al. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality , 2018, Rheumatology.
[96] M. Mayes,et al. Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry , 2018, The Journal of Rheumatology.
[97] V. Steen,et al. Long‐Term Outcomes in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS) , 2018, Chest.
[98] Charlie Little,et al. The Role of Hospital Medicine in Emergency Preparedness: A Framework for Hospitalist Leadership in Disaster Preparedness, Response, and Recovery , 2018, Journal of hospital medicine.
[99] B. Thombs,et al. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts , 2018, Rheumatology.
[100] J. D. de Vries-Bouwstra,et al. Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. , 2018, Clinical and experimental rheumatology.
[101] N. Ortego-Centeno,et al. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study , 2018, Clinical Rheumatology.
[102] J. Gordon,et al. Changes in hemodynamic classification over time are common in systemic sclerosis-associated pulmonary hypertension: insights from the PHAROS cohort , 2018, Pulmonary circulation.
[103] Flora Kisuule,et al. Hospital medicine beyond the United States , 2018, International journal of general medicine.
[104] D. Huscher,et al. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group , 2018, Arthritis Research & Therapy.
[105] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[106] R. Ríos-Fernandez,et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group , 2018, Rheumatology International.
[107] D. Furst,et al. Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. , 2017, Joint, bone, spine : revue du rhumatisme.
[108] S. Pocock,et al. Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study , 2017, Annals of internal medicine.
[109] N. Ortego-Centeno,et al. Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry. , 2017, Seminars in arthritis and rheumatism.
[110] R. Roussel,et al. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes , 2017, Diabetes, obesity & metabolism.
[111] Neha J. Pagidipati,et al. Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes , 2017, The New England journal of medicine.
[112] N. Ortego-Centeno,et al. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. , 2017, Clinical and experimental rheumatology.
[113] D. Pascual-Figal,et al. Trends and Characteristics of Hospitalization for Heart Failure in a Population Setting From 2003 to 2013. , 2017, Revista espanola de cardiologia.
[114] M. Boubaya,et al. Mapping and predicting mortality from systemic sclerosis , 2017, Annals of the rheumatic diseases.
[115] S. Griffin,et al. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes , 2017, Diabetologia.
[116] N. Ortego-Centeno,et al. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort. , 2017, Autoimmunity reviews.
[117] B. Zinman,et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes , 2017, The New England journal of medicine.
[118] C. Hill,et al. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension , 2017, Arthritis Research & Therapy.
[119] R. Milewski,et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study , 2017, Rheumatology.
[120] E. Hachulla,et al. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening , 2017, The Journal of Rheumatology.
[121] Rosa M. Estrada-Y.-Martin,et al. Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis , 2017, The Journal of Rheumatology.
[122] K. Khunti,et al. Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data , 2017, Diabetes, obesity & metabolism.
[123] N. Ortego-Centeno,et al. Changes in the pattern of death of 987 patients with systemic sclerosis from 1990 to 2009 from the nationwide Spanish Scleroderma Registry (RESCLE). , 2017, Clinical and experimental rheumatology.
[124] B. Thombs,et al. Using Optimal Test Assembly Methods for Shortening Patient‐Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale‐6: A Scleroderma Patient‐Centered Intervention Network Cohort Study , 2016, Arthritis care & research.
[125] M. Hudson,et al. Anti-HMGCR antibodies in systemic sclerosis , 2016, Medicine.
[126] K. Dharmarajan. Comprehensive Strategies to Reduce Readmissions in Older Patients With Cardiovascular Disease. , 2016, The Canadian journal of cardiology.
[127] C. Denton,et al. UK Scleroderma Study Group (UKSSG) guidelines on the diagnosis and management of scleroderma renal crisis. , 2016, Clinical and experimental rheumatology.
[128] U. Müller-Ladner,et al. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study , 2016, PloS one.
[129] J. C. Callejas Rubio,et al. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry. , 2016, Seminars in arthritis and rheumatism.
[130] S. Proudman,et al. Risk factors for development of pulmonary arterial hypertension in Australian systemic sclerosis patients: results from a large multicenter cohort study , 2016, BMC Pulmonary Medicine.
[131] Lawrence A Leiter,et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.
[132] R. Wachter,et al. Zero to 50,000 - The 20th Anniversary of the Hospitalist. , 2016, The New England journal of medicine.
[133] M. Mayes,et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations , 2016, Medicine.
[134] J. Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[135] M. Hudson,et al. Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study , 2016, Arthritis care & research.
[136] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[137] M. Hellmich,et al. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients , 2016, The Journal of Rheumatology.
[138] S. Solomon,et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.
[139] R. Chang,et al. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. , 2015, Seminars in arthritis and rheumatism.
[140] S. Proudman,et al. Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis , 2015, Internal medicine journal.
[141] B. Griffiths,et al. Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. , 2015, Rheumatology.
[142] M. Stumvoll,et al. Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients , 2015, Diabetes, obesity & metabolism.
[143] D. Furst,et al. Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis–Related Pulmonary Arterial Hypertension , 2015, Arthritis & rheumatology.
[144] A. Conde-Martel,et al. Prevalencia y significado pronóstico de la comorbilidad en la insuficiencia cardiaca , 2015 .
[145] J. Callejas-Rubio,et al. Registry of the Spanish Network for Systemic Sclerosis , 2015, Medicine.
[146] Flora Kisuule,et al. Hospitalists and Their Impact on Quality, Patient Safety, and Satisfaction. , 2015, Obstetrics and gynecology clinics of North America.
[147] M. Mayes,et al. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects , 2015, Autoimmunity.
[148] U. Müller-Ladner,et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database , 2015, Annals of the rheumatic diseases.
[149] J. Ena,et al. Hyperglycemia management in patients admitted to internal medicine in Spain: A point-prevalence survey examining adequacy of glycemic control and guideline adherence. , 2015, European journal of internal medicine.
[150] D. Furst,et al. Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.
[151] U. Müller-Ladner,et al. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. , 2015, Annals of the rheumatic diseases.
[152] J. Cleland,et al. The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis , 2015, Annals of Internal Medicine.
[153] M. Humbert,et al. Validation of two predictive models for survival in pulmonary arterial hypertension , 2015, European Respiratory Journal.
[154] B. Thombs,et al. Major Depression Diagnoses Among Patients With Systemic Sclerosis: Baseline and One‐Month Followup , 2015, Arthritis care & research.
[155] D. M. van der Heijde,et al. Digital ulcers predict a worse disease course in patients with systemic sclerosis , 2015, Annals of the rheumatic diseases.
[156] U. Müller-Ladner,et al. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population , 2015, Rheumatology.
[157] F. Formiga,et al. Comorbidity in heart failure. Results of the Spanish RICA Registry. , 2014, QJM : monthly journal of the Association of Physicians.
[158] M. Hudson,et al. Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects , 2014, The Journal of Rheumatology.
[159] R. Simms,et al. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. , 2014, Clinical and experimental rheumatology.
[160] M. Hudson,et al. Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects. , 2014, Clinical and experimental rheumatology.
[161] S. Jimenez,et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study , 2014, Annals of the rheumatic diseases.
[162] K. Simpson,et al. New hospital telemedicine services: potential market for a nighttime telehospitalist service. , 2014, Telemedicine journal and e-health : the official journal of the American Telemedicine Association.
[163] M. Mayes,et al. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. , 2014, Seminars in arthritis and rheumatism.
[164] M. Hudson,et al. Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests , 2014, The Journal of Rheumatology.
[165] M. Hudson,et al. Clinical and Serologic Correlates of Anti‐PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients , 2014, Arthritis & rheumatology.
[166] M. Hudson,et al. Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort , 2014, Scandinavian journal of rheumatology.
[167] M. Baron,et al. Frailty Index to Measure Health Status in People with Systemic Sclerosis , 2014, The Journal of Rheumatology.
[168] R. Gómez-Huelgas,et al. Frequency of hypoglycemia and its impact on length of stay, mortality, and short-term readmission in patients with diabetes hospitalized in internal medicine wards. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[169] F. Formiga,et al. Basal functional status predicts three-month mortality after a heart failure hospitalization in elderly patients - the prospective RICA study. , 2014, International journal of cardiology.
[170] D. Huscher,et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group , 2014, Annals of the rheumatic diseases.
[171] M. Worm,et al. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis , 2014, Annals of the rheumatic diseases.
[172] D. Khanna,et al. Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study , 2014, The Journal of Rheumatology.
[173] P. Boracchi,et al. Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. , 2013, Microvascular research.
[174] B. Thombs,et al. Sleep disturbances in systemic sclerosis: evidence for the role of gastrointestinal symptoms, pain and pruritus. , 2013, Rheumatology.
[175] U. Müller-Ladner,et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis , 2013, Annals of the rheumatic diseases.
[176] M. Hudson,et al. Systemic Sclerosis in Canada’s North American Native Population: Assessment of Clinical and Serological Manifestations , 2013, The Journal of Rheumatology.
[177] L. Czirják,et al. Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study , 2013, Annals of the rheumatic diseases.
[178] M. Hudson,et al. Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in Systemic Sclerosis , 2013, The Journal of Rheumatology.
[179] Karl Swedberg,et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. , 2013, European heart journal.
[180] A. Tyndall,et al. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. , 2013, Rheumatology.
[181] R. Caporali,et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. , 2013, Clinical and experimental rheumatology.
[182] M. Hudson,et al. Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group , 2013, The Journal of Rheumatology.
[183] U. Müller-Ladner,et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study , 2012, Annals of the rheumatic diseases.
[184] U. Müller-Ladner,et al. Juvenile and young adult-onset systemic sclerosis share the same organ involvement in adulthood: data from the EUSTAR database. , 2012, Rheumatology.
[185] R. Steele,et al. Longitudinal Study of Renal Function in Systemic Sclerosis , 2012, The Journal of Rheumatology.
[186] M. Humbert,et al. TGFβ receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients , 2012, Annals of the rheumatic diseases.
[187] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.
[188] J. Callejas-Rubio,et al. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. , 2012, Seminars in arthritis and rheumatism.
[189] R. Steele,et al. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis , 2012, Arthritis care & research.
[190] Sameer Ather,et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. , 2012, Journal of the American College of Cardiology.
[191] R. Steele,et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis , 2012, Arthritis Research & Therapy.
[192] B. Levis,et al. Rates and correlates of sexual activity and impairment among women with systemic sclerosis , 2012, Arthritis care & research.
[193] M. Mayes,et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry , 2012, Annals of the rheumatic diseases.
[194] P. Nash,et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort , 2011, Arthritis research & therapy.
[195] B. Thombs,et al. Measuring Pain in Systemic Sclerosis: Comparison of the Short-form McGill Pain Questionnaire Versus a Single-item Measure of Pain , 2011, The Journal of Rheumatology.
[196] M. Meurer,et al. Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features , 2011, Arthritis research & therapy.
[197] R. Gomis,et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study , 2011, Diabetologia.
[198] M. Hudson,et al. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[199] V. Steen,et al. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population , 2011, The Journal of Rheumatology.
[200] R. Steele,et al. Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis , 2011, The Journal of Rheumatology.
[201] L. Mouthon,et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. , 2011, Rheumatology.
[202] A. Gabrielli,et al. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres , 2011, Annals of the rheumatic diseases.
[203] M. Mayes,et al. Anti-Fibrillarin Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis , 2011, The Journal of Rheumatology.
[204] M. Bernabeu-Wittel,et al. Development of a new predictive model for polypathological patients. The PROFUND index. , 2011, European journal of internal medicine.
[205] Oliver Distler,et al. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research , 2011, Annals of the rheumatic diseases.
[206] M. Baron,et al. Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry , 2011, Arthritis care & research.
[207] M. L. Lopes,et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group , 2010, Annals of the rheumatic diseases.
[208] A. Forbes,et al. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. , 2010, Rheumatology.
[209] M. Matucci-Cerinic,et al. Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database , 2010, The Journal of Rheumatology.
[210] M. Humbert,et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.
[211] E. Feierl,et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.
[212] M. Hudson,et al. Systemic Sclerosis: Establishing Diagnostic Criteria , 2010, Medicine.
[213] A. Silman,et al. Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis , 2010, The Journal of Rheumatology.
[214] R. Steele,et al. Malnutrition Is Common in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group Database , 2009, The Journal of Rheumatology.
[215] R. Steele,et al. Work Disability in Systemic Sclerosis , 2009, The Journal of Rheumatology.
[216] T. Therneau,et al. Hospitalizations after heart failure diagnosis a community perspective. , 2009, Journal of the American College of Cardiology.
[217] C. Denton,et al. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. , 2009, Rheumatology.
[218] M. Humbert,et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. , 2009, Arthritis and rheumatism.
[219] R. Steele,et al. Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis , 2009, The Journal of Rheumatology.
[220] J. Gerss,et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors , 2009, The British journal of dermatology.
[221] W. Lehmacher,et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy , 2009, Arthritis research & therapy.
[222] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[223] M. Hudson,et al. The cost of systemic sclerosis. , 2008, Arthritis and rheumatism.
[224] W. Lehmacher,et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register. , 2008, Rheumatology.
[225] M. Hudson,et al. Reports of abnormal cervical cancer screening tests in systemic sclerosis. , 2008, Rheumatology.
[226] M. Matucci-Cerinic,et al. The EULAR Scleroderma Trials And Research group (EUSTAR): an international framework for accelerating scleroderma research , 2008, Current opinion in rheumatology.
[227] R. Landewé,et al. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research , 2008, Annals of the rheumatic diseases.
[228] M. Humbert,et al. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study , 2008, Rheumatology.
[229] U. Müller-Ladner,et al. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database , 2008, Annals of the rheumatic diseases.
[230] W. Lehmacher,et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement , 2008, Rheumatology.
[231] G. Riemekasten,et al. Management of cutaneous vascular complications in systemic scleroderma: experience from the German network , 2008, Rheumatology International.
[232] R. Steele,et al. Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. , 2008, Arthritis and rheumatism.
[233] M. Aringer,et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case–control study , 2007, Annals of the rheumatic diseases.
[234] C. Denton,et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. , 2007, Rheumatology.
[235] D. Furst,et al. The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis , 2007, Annals of the rheumatic diseases.
[236] U. Müller-Ladner,et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.
[237] P. Emery,et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.
[238] M. Humbert,et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.
[239] M. Humbert,et al. Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.
[240] C. Lang,et al. Non-cardiac comorbidities in chronic heart failure , 2006, Heart.
[241] M. Humbert,et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.
[242] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[243] M. Matucci-Cerinic,et al. Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database , 2005, Annals of the rheumatic diseases.
[244] N. Ramírez-Duque,et al. Incidencia y características clínicas de los pacientes con pluripatología ingresados en una unidad de medicina interna , 2005 .
[245] Brenda W Gillespie,et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. , 2003, Arthritis and rheumatism.
[246] W. Lim,et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study , 2003, Thorax.
[247] E. Segovia,et al. Prevalence of heart failure in Asturias (a region in the north of Spain). , 2001, The American journal of cardiology.
[248] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[249] K. Flaherty,et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. , 1998, Chest.
[250] M. Ahern,et al. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. , 1995, Australian and New Zealand journal of medicine.
[251] C. Black. Scleroderma—clinical aspects , 1993, Journal of internal medicine.
[252] T. Medsger,et al. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.
[253] R. Davidson-Lamb,et al. Scleroderma , 1977, Anaesthesia.
[254] A. Feinstein,et al. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. , 1974, Journal of chronic diseases.
[255] A. Blenkinsop. World Health , 1957, Royal Society of Health journal.
[256] C. E.. WHO Coronavirus Disease (COVID-19) Dashboard , 2020 .
[257] A. Singh,et al. Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials , 2019, Indian journal of endocrinology and metabolism.
[258] B. Thombs,et al. Physical or Occupational Therapy Utilization in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. , 2019, The Journal of rheumatology.
[259] W. E. Sanabria,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. , 2019, Lancet.
[260] J. Ena,et al. Derivation and validation model for hospital hypoglycemia. , 2018, European journal of internal medicine.
[261] D. Furst,et al. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. , 2017, Clinical and experimental rheumatology.
[262] S. Proudman,et al. Validity of the Workers Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) in patients with systemic sclerosis. , 2017, Clinical and experimental rheumatology.
[263] C. Viscoli,et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. , 2016, The New England journal of medicine.
[264] Thomas Hügle,et al. Late-onset systemic sclerosis--a systematic survey of the EULAR scleroderma trials and research group database. , 2011, Rheumatology.
[265] M. Baron,et al. Registries in systemic sclerosis: a worldwide experience. , 2011, Rheumatology.
[266] S. Schinner. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[267] J. R. Banegas,et al. Situación epidemiológica de la insuficiencia cardiaca en España , 2006 .
[268] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.